APC
CTSO icon

Aspire Private Capital’s Cytosorbents Corp CTSO Stock Holding History

Aspire Private Capital’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-85
Closed -$662 – 558
2018
Q4 		$1K Buy
+85
New +$844 ﹤0.01% 454

Other funds holding CTSO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Aspire Private Capital's CTSO Position: Q1 2019 in Review

Aspire Private Capital sold out of Cytosorbents Corp (CTSO) in Q1 2019, closing a stake of 85 shares — an estimated $662 sold.

Aspire Private Capital first reported a position in CTSO in Q4 2018 and held it in 1 quarter. The position peaked at $1K in Q4 2018. 77 funds tracked by Wall St. Rank hold CTSO as of Q1 2019.

  • Aspire Private Capital reported no remaining Cytosorbents Corp position as of Q1 2019 after selling out during the quarter.
  • Aspire Private Capital sold 85 Cytosorbents Corp shares in Q1 2019, an estimated $662.
  • Aspire Private Capital first reported a position in Cytosorbents Corp in Q4 2018 and held it in 1 quarter.
  • Aspire Private Capital's Cytosorbents Corp position peaked at $1K in Q4 2018.
  • 77 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2019.

Based on Aspire Private Capital's 13F filing for Q1 2019, filed 13 May 2019.